Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

- PMLiVE

AZ and Novartis ‘most exposed’ to Senate pricing proposals

Most expensive therapies will be penalised

The most annoying ‘F’ word in healthcare

Why fail first policies are an ugly metaphor for larger issues

- PMLiVE

Pfizer set to unveil Mylan merger and spin-off

Follows consumer health deal with GSK

- PMLiVE

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

GW Pharma’s Epidyolex also on the recommended list

- PMLiVE

Dupixent drives Sanofi again, but other new drugs are lagging

Reported loss due to restructuring

Jan Steele, Lucid COO and co-founder reveals where Lucid Group’s new home will be at its Summer Meeting!

Lucid Group Communications Limited

Roche Basel Switzerland

New products help lift Roche outlook despite biosimilar onslaught

Two new cancer therapies approved in Q2

- PMLiVE

PhRMA opposed to Senate drug price control plans

But has bipartisan support and Trump backing

- PMLiVE

Lynparza cleared as ovarian cancer maintenance therapy on Cancer Drugs Fund

Deal done with NHS England just weeks after EU approval

Bristol Myers Squibb logo

Opdivo trial overshadows BMS financial results

Hope remains in Celgene merger

ABPI Patient Sourcebook

A patient view on the ABPI’s patient collaboration sourcebook

Last month, the ABPI released a much-in-demand document: The Working with Patients and Patient Organisations sourcebook.

Cuttsy + Cuttsy

- PMLiVE

Life sciences and NHS feature in Johnson speech – but Brexit promises predominate

GSK leader warns again on no-deal

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links